Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.
ESC HF 2018 A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.
In type 2 diabetic patients with a history of CABG, empagliflozin reduced significantly CV- and all-cause mortality, HF hospitalization, and incident or worsening nephropathy compared with placebo.
Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.
Obesity in childhood that persists or worsens during adulthood is associated with higher risks of developing hypertension, T2DM, and dyslipidemia.
Semaglutide had a comparable efficacy and safety profile in non-elderly and elderly patients with type 2 diabetes.
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.
Compared with enalapril, sacubitril/valsartan led to a slower rate of decrease in the estimated glomerular filtration rate, particularly in type 2 diabetic patients.
Visit-to-visit variability in fasting measurements of HDL-c, TG, and LDL-c is predictive of coronary events, CV events, and TG and LDL-c variability is also predictive of incident diabetes.
An analysis of EXAMINE shows that in diabetic patients with a recent acute coronary syndrome, the combination of metformin, sulfonylurea and alogliptin was well tolerated.
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.